NGN BioMed Opportunity II, L.P.

Overview

NGN BioMed Opportunity II, L.P. is a venture capital firm dedicated to healthcare investing, focusing on ventures with the potential to achieve above-average private equity returns with an emphasis on later-stage investments. The firm has flexibility to invest in a broad cross-section of healthcare and biotechnology segments, including drug products, medical devices, and other healthcare segments like services. The funds are diversified by stage, from later-stage to selected early-stage opportunities, as well as by geography, investing predominantly in the US and Europe. The firm has a professional team and advisors with exceptional investment and management backgrounds in healthcare and venture capital from leading institutions on a global basis. NGN’s professionals were directly involved in transformational developments in healthcare that led to significant realizations for investors. NGN’s advisors are recognized experts in their respective fields of healthcare, science, and corporate value creation and work actively with NGN’s professionals. Collectively, NGN’s professionals and advisors bring substantial value creation achievements and commercial expertise in healthcare ventures to the investments of NGN BioMed Opportunity I and NGN BioMed Opportunity II and their respective portfolio companies. NGN BioMed Opportunity II, L.P. has been involved in several notable investments, including leading a $15 million Series B financing of Cerapedics, Inc., a medical device company developing a bone graft substitute for use in spinal fusion surgery and other orthopedic procedures. Additionally, the firm co-led an initial investment of a targeted $30 million Series A financing of Vivaldi Biosciences, Inc., an emerging flu vaccine company developing unique live attenuated vaccines for seasonal and pandemic influenza. These investments highlight NGN BioMed Opportunity II's commitment to advancing healthcare through strategic venture capital engagements.